Targeted Therapies for BRAF-Mutant Metastatic Melanoma

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cutaneous Melanoma

• Publication date

  2018-12-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-3-319-46029-1_40-1
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma

  2018cited by this paper
• Abstract B015: An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer

  2018cited by this paper
• Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

  2018cited by this paper
• Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

  2018cited by this paper
• Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

  2018cited by this paper
• Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.

  2017cited by this paper
• A review of binimetinib for the treatment of mutant cutaneous melanoma.

  2017cited by this paper
• Development of encorafenib for BRAF-mutated advanced melanoma

  2017cited by this paper
• First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

  2017cited by this paper
• Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

  2017cited by this paper
• Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

  2017cited by this paper
• Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.

  2016cited by this paper
• Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

  2016cited by this paper
• MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.

  2016cited by this paper
• JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma

  2016cited by this paper
• Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

  2016cited by this paper
• A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

  2016cited by this paper
• Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum

  2016cited by this paper
• Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

  2016cited by this paper
• Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.

  2016cited by this paper
• Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer

  2016cited by this paper
• Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

  2016cited by this paper
• Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

  2015cited by this paper
• Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis

  2015cited by this paper
• Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

  2015cited by this paper
• Microphthalmia‐associated transcription factor in melanoma development and MAP‐kinase pathway targeted therapy

  2015cited by this paper
• RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

  2015cited by this paper
• Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

  2015cited by this paper
• Fibroblast-derived Neuregulin 1 Promotes Compensatory ErbB3 Receptor Signaling in Mutant BRAF Melanoma*

  2015cited by this paper
• Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

  2015cited by this paper
• Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells

  2015cited by this paper
• BRAF inhibition generates a host/tumor niche that mediates therapeutic escape

  2015cited by this paper
• Wnt5A promotes an adaptive, senescent‐like stress response, while continuing to drive invasion in melanoma cells

  2015cited by this paper
• Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma

  2015cited by this paper
• The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

  2015cited by this paper
• BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms.

  2015cited by this paper
• Improved overall survival in melanoma with combined dabrafenib and trametinib.

  2015cited by this paper
• Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

  2015cited by this paper
• Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

  2015cited by this paper
• RAF inhibitors that evade paradoxical MAPK pathway activation

  2015cited by this paper
• Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

  2014cited by this paper
• Molecular Pathways Molecular Pathways : Targeting NRAS in Melanoma and Acute Myelogenous Leukemia

  2014cited by this paper
• The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.

  2014cited by this paper
• Targeting RAS–ERK signalling in cancer: promises and challenges

  2014cited by this paper
• Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

  2014cited by this paper
• A stress-induced early innate response causes multidrug tolerance in melanoma

  2014cited by this paper
• Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

  2014cited by this paper
• Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

  2014cited by this paper
• Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

  2014cited by this paper
• Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

  2014cited by this paper
• Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

  2014cited by this paper
• Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

  2014cited by this paper
• MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

  2014cited by this paper
• A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.

  2014cited by this paper
• Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

  2014cited by this paper
• Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

  2013cited by this paper
• Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.

  2013cited by this paper
• IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase–driven tumors

  2013cited by this paper
• Clinical responses to selumetinib (AZD6244; ARRY‐142886)‐based combination therapy stratified by gene mutations in patients with metastatic melanoma

  2013cited by this paper
• Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

  2013cited by this paper
• Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

  2013cited by this paper
• Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.

  2013cited by this paper
• Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

  2013cited by this paper
• Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.

  2013cited by this paper
• Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

  2013cited by this paper
• BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

  2013cited by this paper
• Hepatotoxicity with combination of vemurafenib and ipilimumab.

  2013cited by this paper
• A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

  2013cited by this paper
• Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

  2012cited by this paper
• Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF

  2012cited by this paper
• Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

  2012cited by this paper
• Progression of RAS-mutant leukemia during RAF inhibitor treatment.

  2012cited by this paper
• BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

  2012cited by this paper
• Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012cited by this paper
• Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion

  2012cited by this paper
• Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

  2012cited by this paper
• RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors

  2012cited by this paper
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

  2012cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

  2011cited by this paper
• Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

  2011cited by this paper
• Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

  2010cited by this paper
• COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies

  2010cited by this paper
• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

  2010cited by this paper
• MEK1 mutations confer resistance to MEK and B-RAF inhibition

  2009cited by this paper
• Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi

  2008cited by this paper
• Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

  2008cited by this paper
• Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

  2005cited by this paper
• A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer

  2005cited by this paper
• Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells.

  2002cited by this paper

• No citing papers are available for this paper.